Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings
CNBC Earnings
Barrons Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

Stocktwits
MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-

Kyverna Therapeutics, Inc. Common Stock | KYTX

AI Analysis of Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics had a rough day and is now down -5.43%. Investors weren't too impressed with the future outlook for the asset which caused some selling on weak demand. It looks like KYTX may be interacting with a slightly angled support line. This area could represent a pivot point that it moves up from. In addition to being near an angled support line KYTX is near a weak support line. We'll see if it bounces off or heads lower. KYTX hasn't had very clear momentum over the last 3 months in either direction. Which makes it a little harder to predict. But hasn't shown the selling pressure to make me feel certain it will break through the line.

If we get a reversal off of support and Kyverna Therapeutics starts moving up, it can probably get to $9.98 at which point it'll need to break through that resistance level in order to keep moving higher. If it punches through this support level, it can easily push down to $6.7 where it may meet further support, hopefully it can consolidate around that point.


Last analyzed on 2026-07-23

Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-